High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for myelodysplastic syndromes (MDS).
• Current risk stratification tools like the International Prognostic Scoring System have limitations.
• Hypomethylating agents (HMAs) show efficacy in high-risk MDS but have limitations in response rates and survival benefit.

Purpose of the Study:

• To evaluate the role of hypomethylating agents in optimizing treatment for myelodysplastic syndromes (MDS) patients undergoing allogeneic HCT.
• To discuss the evolving landscape of MDS treatment considering advancements in drug therapy and transplant strategies.

Main Methods:

• Review of current literature on hypomethylating agents (azacitidine, decitabine) and allogeneic HCT for MDS.
• Analysis of treatment decision complexities arising from evolving therapeutic options.
• Consideration of modern transplant strategies and alternative donor sources.

Main Results:

• Approximately 50% of high-risk MDS patients do not achieve a meaningful response to HMAs.
• HMAs provide a modest survival benefit with a median response duration of 13 months.
• Advancements in risk models and transplant strategies are increasing access to curative treatment.

Conclusions:

• Hypomethylating agents can be utilized to optimize disease response in MDS patients prior to, and potentially after, allogeneic HCT.
• Treatment decisions for MDS are becoming more complex due to evolving drug therapies and HCT modalities.
• Integrating HMAs with HCT offers a promising strategy for improving outcomes in myelodysplastic syndromes.